SCHEMBL23717441

SCHEMBL23717441

CCNc1ccc(N)c(C(=O)OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
KDM4E B2RXH2 6/20 0.59
GAA P10253 6/20 0.59
HSD17B10 Q99714 3/20 0.59
MAPT P10636 3/20 0.59
HPGD P15428 3/20 0.59
ALOX15 P16050 1/20 0.59
TSHR P16473 1/20 0.59
CFTR P13569 3/20 0.50
GLA P06280 2/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
ATM Q13315 1/20 0.46
EGFR P00533 5/20 0.46
NOX4 Q9NPH5 1/20 0.46
ABL1 P00519 1/20 0.45
TDP1 Q9NUW8 1/20 0.41
CDK1 P06493 1/20 0.40
THRB P10828 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17779229 0.83 IKBKB (0.45) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL21900515 0.81 KMT2A (0.58) ALDH1A1KDM4EGAAMAPTTSHR
SCHEMBL15763208 0.79 SMN1; SMN2 (0.64) GAAHSD17B10HPGDALOX15TSHR
SCHEMBL7458280 0.79 SMN1; SMN2 (0.64) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL221403 0.78 ALDH1A1 (0.81) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL6110454 0.77 TDP1 (0.55) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL25230816 0.77 ALDH1A1 (0.73) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL14214714 0.77 AVPR2 (0.47) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL29035720 0.77 EGFR (0.43) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL19674302 0.77 LRRK2 (0.42) ALDH1A1KDM4EGAAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210236442-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210236442-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES IAPP, SLC5A2, SLC2A2 ALDH1A1 3985/4885KDM4E 3516/4885GAA 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.